-
-
[1] 庞若, 金波.凡德他尼在非小细胞肺癌治疗中的进展[J].中华临床医师杂志, 2012, 6:8264-8267. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhlcyszz201224084 [2] Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phase Ⅲ trial[J]. J Clin Oncol, 2012, 30:134-141. doi: 10.1200/jco.2011.35.5040 [3] Drappatz J, Norden AD, Wong ET, et al. phase Ⅰ study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma[J]. Int J Radiat Oncol Biol Phys, 2010, 78:85-90. doi: 10.1016/j.ijrobp.2009.07.1741 [4] Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:a meta-analysis[J]. Lancet Oncol, 2009, 10:559-568. doi: 10.1016/S1470-2045(09)70112-3 [5] Qi WX, Sun YJ, Tang LN. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors:a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2014, 89:394-403. doi: 10.1016/j.critrevonc.2013.10.002 [6] Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature[J]. Am J Physiol Heart Circ Physiol, 2006, 290:H560-H576. doi: 10.1152/ajpheart.00133.2005